» Articles » PMID: 25187312

Immunology of Naturally Transmissible Tumours

Overview
Journal Immunology
Date 2014 Sep 5
PMID 25187312
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Naturally transmissible tumours can emerge when a tumour cell gains the ability to pass as an infectious allograft between individuals. The ability of these tumours to colonize a new host and to cross histocompatibility barriers contradicts our understanding of the vertebrate immune response to allografts. Two naturally occurring contagious cancers are currently active in the animal kingdom, canine transmissible venereal tumour (CTVT), which spreads among dogs, and devil facial tumour disease (DFTD), among Tasmanian devils. CTVT are generally not fatal as a tumour-specific host immune response controls or clears the tumours after transmission and a period of growth. In contrast, the growth of DFTD tumours is not controlled by the Tasmanian devil's immune system and the disease causes close to 100% mortality, severely impacting the devil population. To avoid the immune response of the host both DFTD and CTVT use a variety of immune escape strategies that have similarities to many single organism tumours, including MHC loss and the expression of immunosuppressive cytokines. However, both tumours appear to have a complex interaction with the immune system of their respective host, which has evolved over the relatively long life of these tumours. The Tasmanian devil is struggling to survive with the burden of this disease and it is only with an understanding of how DFTD passes between individuals that a vaccine might be developed. Further, an understanding of how these tumours achieve natural transmissibility should provide insights into general mechanisms of immune escape that emerge during tumour evolution.

Citing Articles

Gene expression in soft-shell clam () transmissible cancer reveals survival mechanisms during host infection and seawater transfer.

Hart S, Garrett F, Kerr J, Metzger M bioRxiv. 2024; .

PMID: 39345472 PMC: 11429866. DOI: 10.1101/2024.09.13.612964.


Bridging clinic and wildlife care with AI-powered pan-species computational pathology.

AbdulJabbar K, Castillo S, Hughes K, Davidson H, Boddy A, Abegglen L Nat Commun. 2023; 14(1):2408.

PMID: 37100774 PMC: 10133243. DOI: 10.1038/s41467-023-37879-x.


Cancer-Immunity Cycle and Therapeutic Interventions- Opportunities for Including Pet Dogs With Cancer.

Von Rueden S, Fan T Front Oncol. 2021; 11:773420.

PMID: 34869014 PMC: 8639699. DOI: 10.3389/fonc.2021.773420.


PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma.

Maekawa N, Konnai S, Nishimura M, Kagawa Y, Takagi S, Hosoya K NPJ Precis Oncol. 2021; 5(1):10.

PMID: 33580183 PMC: 7881100. DOI: 10.1038/s41698-021-00147-6.


The evolution of resistance and tolerance as cancer defences.

Thomas F, Giraudeau M, Gouzerh F, Boutry J, Renaud F, Pujol P Parasitology. 2019; 147(3):255-262.

PMID: 31727197 PMC: 10317655. DOI: 10.1017/S0031182019001501.


References
1.
Murchison E, Schulz-Trieglaff O, Ning Z, Alexandrov L, Bauer M, Fu B . Genome sequencing and analysis of the Tasmanian devil and its transmissible cancer. Cell. 2012; 148(4):780-91. PMC: 3281993. DOI: 10.1016/j.cell.2011.11.065. View

2.
Rosenberg A, Singer A . Cellular basis of skin allograft rejection: an in vivo model of immune-mediated tissue destruction. Annu Rev Immunol. 1992; 10:333-58. DOI: 10.1146/annurev.iy.10.040192.002001. View

3.
Hsiao Y, Liao K, Hung S, Chu R . Tumor-infiltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGF-beta 1 and restores the lymphokine-activated killing activity. J Immunol. 2004; 172(3):1508-14. DOI: 10.4049/jimmunol.172.3.1508. View

4.
Powers R . Immunologic properties of canine transmissible venereal sarcoma. Am J Vet Res. 1968; 29(8):1637-45. View

5.
Trail P, Yang T . Canine transmissible venereal sarcoma: quantitation of T-lymphocyte subpopulations during progressive growth and spontaneous tumor regression. J Natl Cancer Inst. 1985; 74(2):461-7. View